| For: | Li ZP, Luo C, Yu XM, Ye LY, Sun D, Duan CZ, Xu SY, Zeng MQ, Xu H, Peng ZY, Wang P, Wang YB, Ruan WJ, Xue ME, Zhang CJ, He DJ. Diabetic bone fragility through advanced glycation end product-collagen axis: Mechanisms and therapy of sodium glucose cotransporter 2 inhibitors. World J Diabetes 2025; 16(10): 111813 [PMID: 41113476 DOI: 10.4239/wjd.v16.i10.111813] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v16/i10/111813.htm |
| Number | Citing Articles |
| 1 |
Hind Alshamsi, Duha Alnaqbi, Charu Sharma, Romona D Govender, Raya Almazrouei. Romosozumab Efficacy in Osteoporosis: Influence of Diabetes and Previous Antiresorptive Therapy: A Single Centre Experience. Clinical Medicine Insights: Endocrinology and Diabetes 2026; 19 doi: 10.1177/11795514261440728
|
| 2 |
Mohammad N Khan, Anisha Tanwar, Mandayal Jamatia. Association of Bone Metabolism Markers with Glycemic Parameters in Type 2 Diabetes Mellitus: Insights from a Cross-sectional Study on Serum Osteocalcin, Vitamin D, and Parathyroid Hormone. Indian Journal of Medical Biochemistry 2026; 30(2): 172 doi: 10.5005/jp-journals-10054-0329
|
| 3 |
彩霞 马. Effects of Different Antidiabetic Drugs on Sarcopenia and Bone Metabolism. Advances in Clinical Medicine 2026; 16(02): 1414 doi: 10.12677/acm.2026.162528
|
| 4 |
Han Su, Chengfeng Fu, Pingping Wang, Yingying Zhang. Long-term trajectories and cumulative exposure of the triglyceride–glucose–frailty index in relation to hip fracture risk: evidence from a large-scale population-based cohort. Archives of Osteoporosis 2026; 21(1) doi: 10.1007/s11657-026-01683-z
|